Valneva SE - American Depositary Shares (NQ:VALN)

5.815 +0.075 (+1.31%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Valneva SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday ↗

August 19, 2024

Via Benzinga

Analyst Scoreboard: 8 Ratings For Valneva ↗

August 14, 2024

Via Benzinga

VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q2 2024 ↗

August 13, 2024

VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

3 Promising Biotech Stocks You Can Pick Up for Less Than $10 ↗

July 29, 2024

Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price.

Via InvestorPlace

What Analysts Are Saying About Valneva Stock ↗

July 22, 2024

Via Benzinga

Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026 ↗

July 18, 2024

Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025...

Via Benzinga

The Analyst Landscape: 6 Takes On Valneva ↗

June 24, 2024

Via Benzinga

What Analysts Are Saying About Valneva Stock ↗

May 31, 2024

Via Benzinga

Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data ↗

May 13, 2024

Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil.

Via Benzinga

VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024 ↗

May 13, 2024

VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Cracking The Code: Understanding Analyst Reviews For Valneva ↗

May 08, 2024

Via Benzinga

What Analysts Are Saying About Valneva Stock ↗

March 22, 2024

Via Benzinga

VALN Stock Earnings: Valneva Misses Revenue for Q4 2023 ↗

March 20, 2024

VALN stock results show that Valneva missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday ↗

March 19, 2024

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

Via Benzinga

Topics Stocks

Expert Ratings for Valneva ↗

December 04, 2023

Via Benzinga

Analyst Ratings for Valneva ↗

November 10, 2023

Via Benzinga

Analyst Ratings for Valneva ↗

September 07, 2023

Via Benzinga

Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday ↗

March 08, 2024

U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.

Via Benzinga

Topics Stocks

Novavax’s dispute resolution and upcoming earnings call

February 23, 2024

Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.

Via MarketBeat

Topics Earnings

Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline ↗

February 05, 2024

Valneva sells FDA Priority Review Voucher for $103 million after FDA approval of Ixchiq, the world's first licensed chikungunya vaccine. Proceeds to boost R&D projects.

Via Benzinga

McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday ↗

February 05, 2024

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults ↗

December 04, 2023

Valneva SE (NASDAQ: VALN) reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of...

Via Benzinga

FDA Approves World's First Mosquito-Borne Chikungunya Vaccine ↗

November 10, 2023

The FDA approved Valneva SE's (NASDAQ: VALN) Chikungunya single-dose vaccine in individuals

Via Benzinga

Pfizer, Valneva's Tick-Borne Infection Shot: Companies Say 'Positive' Result For Lyme Disease Vaccine Candidate Booster ↗

September 07, 2023

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) released pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate,

Via Benzinga

7 Unmatched Stocks: The Untapped Goldmines to Buy Now. ↗

August 24, 2023

Although these ideas for stocks with potential present high risk, they may also offer robust, even game-changing returns.

Via InvestorPlace

Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 14, 2023

Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 14, 2023

Via Benzinga

AMC Entertainment, Nikola, Cleveland-Cliffs And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

August 14, 2023

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Top 5 Health Care Stocks That May Crash This Month ↗

June 22, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Bavarian Nordic Beefs Up Chikungunya Vaccine Race With Valneva With Encouraging Late-Stage Trial Data ↗

June 20, 2023

Bavarian Nordic A/S's (OTC: BVNRY) phase 3 chikungunya virus vaccine (CHIKV VLP (PXVX0317) clinical trial has hit its primary endpoint in

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.